DRUG DELIVERY DEVICES


Injectable drug delivery solutions for clinical trials


Ziv Cahani, VP of business development and marketing at DALI Medical Devices, discusses how advanced drug delivery devices can help drive the success of clinical trials of injectable drugs.


increasingly decentralised and hybrid or remote. In April to May 2020, 73% of clinical professionals surveyed by clinical trials services company ERT said that virtualisation of clinical trials was very or extremely critical to their organisations; and, given the ongoing pandemic situation, we can expect it to continue growing. Indeed, in March 2020 (and updated most recently in August 2021), the US Food and Drug Administration issued pandemic-specific guidelines that included recommendations for virtual or hybrid execution.


O 56 | Outsourcing in Clinical Trials Handbook


ver the past few years, and particularly since the outbreak of the COVID-19 pandemic, clinical trials have become


Take trials out of the clinic to keep patients in Aside from the exigencies of COVID-19, patient participation is one of the key challenges in conducting clinical trials. It is commonly recognised that around 85% of studies fail to meet recruitment targets and as many as 50% of trials are delayed due to recruitment issues. And then, once enough patients are enrolled and the trial starts, an average of 30% drop out, requiring either over-recruitment to begin with or leading to further delays while replacing the lost patients, all of which can add significant costs. Patient inconvenience is a major reason behind low recruitment and retention rates. Faced with


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100